EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieMultizentrische StudieOpen Access · CC BY 4.0

A propensity score‐matched comparison of neoadjuvant chemoradiotherapy with cisplatin‐ 5FU and carboplatin–paclitaxel in locally advanced esophageal squamous cell carcinoma: A Turkish oncology group study

Fatih Gürler iD, Fatih Tay iD, Zehra Sucuoğlu İşleyen iD, Tahir Yerlikaya iD, Engin Hendem iD, Selin Aktürk Esen iD, Osman Sütçüoğlu iD, Deniz Işık, Büşra Niğdelioğlu, Miraç Özen, Elif Şahin iD, Teoman Şakalar iD und 13 weitere

Cancer Medicine · 2024

DOI: 10.1002/cam4.70002 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Fatih Gürler und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey. Hauptthemen laut MEDLINE: Propensity Score, Carboplatin, Cisplatin, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neoadjuvant treatment is the standard treatment in locally advanced ESCC. However, the optimal chemotherapy regimen is not known.

Method

This is a retrospective observational cohort study conducted with propensity score matching. Patients with resectable ESCC from 13 tertiary centers from Türkiye were screened between January 2011 and December 2021. We compared the efficacy and safety of neoadjuvant chemoradiotherapy with the CF and the CROSS regimens in patients with ESCC.

Results

Three hundred and sixty‐two patients were screened. Patients who received induction chemotherapy ( n = 72) and CROSS‐ineligible ( n = 31) were excluded. Two hundred and fifty nine patients received neoadjuvant chemoradiotherapy. After propensity score matching ( n = 97 in both groups), the mPFS was 18.4 months (95% CI, 9.3–27.4) and 25.7 months (95% CI, 15.6–35.7; p = 0.974), and the mOS was 35.2 months (95% CI, 18.9–51.5) and 39.6 months (95% CI 20.1–59.2; p = 0.534), in the CF and the CROSS groups, respectively. There was no difference between subgroups regarding PFS and OS. Compared with the CF group, the CROSS group had a higher incidence of neutropenia (34.0% vs. 62.9%, p < 0.001) and anemia (54.6% vs. 75.3%, p = 0.003) in all grades. On the other hand, there was no significant difference in grade 3–4 anemia, grade 3–4 neutropenia, and febrile neutropenia between groups. There were more dose reductions and dose delays in the CROSS group than in the CF group (11.3% vs. 3.1%, p = 0.026 and 34.0% vs. 17.5%, p = 0.009, respectively). The resection rate was 52.6% in the CF‐RT and 35.1% in the CROSS groups ( p = 0.014).

Conclusion

Favorable PFS and pCR rates and a comparable OS were obtained with the CROSS regimen over the CF regimen as neoadjuvant chemoradiotherapy in patients with ESCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Propensity ScoreCarboplatinCisplatinAntineoplastic Combined Chemotherapy ProtocolsNeoadjuvant TherapyPaclitaxelFluorouracilEsophageal Squamous Cell CarcinomaEsophageal NeoplasmsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedTurkeyChemoradiotherapyAdult

Stichwörter der Autor:innen

CFCROSSesophageal cancerneoadjuvant

Substanzen

CarboplatinCisplatinPaclitaxelFluorouracil

Autor:innen und Institutionen

  • Department of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey.
  • Dr Abdurrahman Yurtaslan Ankara Oncology Teaching and Research Hospital, University of Health Sciences, Ankara, Turkey.
  • Department of Medical Oncology, Bezmi Alem Vakif University, İstanbul, Turkey.
  • Department of Medical Oncology, Antalya Teaching and Research Hospital, Antalya, Turkey.
  • Department of Medical Oncology, Necmettin Erbakan University Faculty of Medicine, Konya, Turkey.
  • Department of Medical Oncology, University of Health Sciences, Ankara City Hospital, Ankara, Turkey.

ORCID-Profile: Fatih Gürler, Fatih Tay, Zehra Sucuoğlu İşleyen, Tahir Yerlikaya, Engin Hendem, Selin Aktürk Esen, Osman Sütçüoğlu, Elif Şahin, Teoman Şakalar, Nilay Şengül Samancı, Özkan Alan, Efnan Algın, Berna Öksüzoğlu, Aydın Yavuz, Osman Yüksel, Ozan Yazıcı, Ahmet Özet, Nuriye Özdemir

Zitieren

APA

Gürler, F., Tay, F., Sucuoğlu İşleyen, Z., Yerlikaya, T., Hendem, E., Esen, S. A., Sütçüoğlu, O., Işık, D., Niğdelioğlu, B., Özen, M., Şahin, E., Şakalar, T., Şengül Samancı, N., Alan, Ö., Hacıbekiroğlu, İ., Algın, E., Yılmaz, M. K., Türk, H. M., Öksüzoğlu, B., …, & Özdemir, N. (2024). A propensity score‐matched comparison of neoadjuvant chemoradiotherapy with cisplatin‐ 5FU and carboplatin–paclitaxel in locally advanced esophageal squamous cell carcinoma: A Turkish oncology group study. Cancer Medicine. https://doi.org/10.1002/cam4.70002

Vancouver

Gürler F, Tay F, Sucuoğlu İşleyen Z, Yerlikaya T, Hendem E, Esen SA, et al. A propensity score‐matched comparison of neoadjuvant chemoradiotherapy with cisplatin‐ 5FU and carboplatin–paclitaxel in locally advanced esophageal squamous cell carcinoma: A Turkish oncology group study. Cancer Medicine. 2024. doi:10.1002/cam4.70002

BibTeX
@article{Grler2024,
  author = {Gürler, Fatih and Tay, Fatih and Sucuoğlu İşleyen, Zehra and Yerlikaya, Tahir and Hendem, Engin and Esen, Selin Aktürk and Sütçüoğlu, Osman and Işık, Deniz and Niğdelioğlu, Büşra and Özen, Miraç and Şahin, Elif and Şakalar, Teoman and Şengül Samancı, Nilay and Alan, Özkan and Hacıbekiroğlu, İlhan and Algın, Efnan and Yılmaz, Melek Karakurt and Türk, Hacı Mehmet and Öksüzoğlu, Berna and Yavuz, Aydın and Yüksel, Osman and Bora, Hüseyin and Yazıcı, Ozan and Özet, Ahmet and Özdemir, Nuriye},
  title = {A propensity score‐matched comparison of neoadjuvant chemoradiotherapy with cisplatin‐ 5FU and carboplatin–paclitaxel in locally advanced esophageal squamous cell carcinoma: A Turkish oncology group study},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70002}
}
Kostenlos starten →